Sectors & IndustriesHealthcareBiotechnology

Best Biotech Stocks to Buy Now (2026)

Top biotech stocks in 2026 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +28.50% per year, and are the best biotech stocks to buy now. Learn More.

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best biotechnology stocks to buy right now are:

Puma Biotechnology (NASDAQ:PBYI) is the #1 top biotech stock out of 609 with a Zen Rating of A. Stocks with a rating of A have had an average return of +28.5% per year. Learn more.

The Component Grade breakdown for Puma Biotechnology (NASDAQ:PBYI) is: Value: A, Growth: C, Momentum: A, Sentiment: B, Safety: C, Financials: A, and AI: B.

Puma Biotechnology (NASDAQ:PBYI) has a Due Diligence Score of 48, which is 24 points higher than the biotech industry average of 24.

PBYI passed 15 out of 33 due diligence checks and has strong fundamentals. Puma Biotechnology has seen its stock return 102.78% over the past year, overperforming other biotech stocks by 166 percentage points.

Puma Biotechnology has an average 1 year price target of $6.00, a downside of -41.29% from Puma Biotechnology's current stock price of $10.22.

Puma Biotechnology stock has a consensus Hold recommendation according to Wall Street analysts. Of the 1 analyst covering Puma Biotechnology, 0% have issued a Strong Buy rating, 0% have issued a Buy, 100% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Regeneron Pharmaceuticals (NASDAQ:REGN) is the #2 top biotech stock out of 609 with a Zen Rating of A. Stocks with a rating of A have had an average return of +28.5% per year. Learn more.

The Component Grade breakdown for Regeneron Pharmaceuticals (NASDAQ:REGN) is: Value: B, Growth: B, Momentum: C, Sentiment: A, Safety: B, Financials: B, and AI: B.

Regeneron Pharmaceuticals (NASDAQ:REGN) has a Due Diligence Score of 47, which is 23 points higher than the biotech industry average of 24.

REGN passed 18 out of 38 due diligence checks and has strong fundamentals. Regeneron Pharmaceuticals has seen its stock return 51.55% over the past year, overperforming other biotech stocks by 115 percentage points.

Regeneron Pharmaceuticals has an average 1 year price target of $904.29, a downside of -7.1% from Regeneron Pharmaceuticals's current stock price of $973.36.

Regeneron Pharmaceuticals stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 24 analysts covering Regeneron Pharmaceuticals, 58.33% have issued a Strong Buy rating, 8.33% have issued a Buy, 33.33% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Beone Medicines (NASDAQ:ONC) is the #3 top biotech stock out of 609 with a Zen Rating of A. Stocks with a rating of A have had an average return of +28.5% per year. Learn more.

The Component Grade breakdown for Beone Medicines (NASDAQ:ONC) is: Value: B, Growth: B, Momentum: B, Sentiment: B, Safety: C, Financials: B, and AI: B.

Beone Medicines (NASDAQ:ONC) has a Due Diligence Score of 28, which is 4 points higher than the biotech industry average of 24.

ONC passed 9 out of 33 due diligence checks and has average fundamentals. Beone Medicines has seen its stock return 13.83% over the past year, overperforming other biotech stocks by 77 percentage points.

Beone Medicines has an average 1 year price target of $421.36, an upside of 18.69% from Beone Medicines's current stock price of $355.00.

Beone Medicines stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 11 analysts covering Beone Medicines, 81.82% have issued a Strong Buy rating, 18.18% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Out of 7 biotech stocks that have issued dividends in the past year, the 3 biotech stocks with the highest dividend yields are:

Oramed Pharmaceuticals (NASDAQ:ORMP) has an annual dividend yield of 6.25%, which is 4 percentage points higher than the biotech industry average of 2.26%.

Oramed Pharmaceuticals's dividend payout ratio of 5.9% indicates that its high dividend yield is sustainable for the long-term.

Novo Nordisk (Ozempic) (NYSE:NVO) has an annual dividend yield of 4.61%, which is 2 percentage points higher than the biotech industry average of 2.26%. Novo Nordisk (Ozempic)'s dividend payout is not stable, having dropped more than 10% nine times in the last 10 years. Novo Nordisk (Ozempic)'s dividend has shown consistent growth over the last 10 years.

Novo Nordisk (Ozempic)'s dividend payout ratio of 46.1% indicates that its high dividend yield is sustainable for the long-term.

Yarrow Bioscience (NASDAQ:YARW) has an annual dividend yield of 2.07%, which is the same as the biotech industry average of 2.26%.

Yarrow Bioscience's dividend payout ratio of -93.5% indicates that its dividend yield might not be sustainable for the long-term.

Biotech stocks were up 1.1% in the last day, and up 0.82% over the last week. Pasithea Therapeutics was the among the top gainers in the biotechnology industry, gaining 44.02% yesterday.

Pasithea Therapeutics shares are trading higher after the company announced the FDA clearance of its IND application for a Phase 2 trial of PAS-004 in patients with NF1-associated cutaneous neurofibromas.

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued biotech stocks right now are:

Harmony Biosciences Holdings (NASDAQ:HRMY) is the most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Harmony Biosciences Holdings has a valuation score of 57, which is 42 points higher than the biotech industry average of 15. It passed 4 out of 7 valuation due diligence checks.

Harmony Biosciences Holdings's stock has gained 26.22% in the past year. It has overperformed other stocks in the biotech industry by 89 percentage points.

Zevra Therapeutics (NASDAQ:ZVRA) is the second most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Zevra Therapeutics has a valuation score of 57, which is 42 points higher than the biotech industry average of 15. It passed 4 out of 7 valuation due diligence checks.

Zevra Therapeutics's stock has gained 0.49% in the past year. It has overperformed other stocks in the biotech industry by 64 percentage points.

Innoviva (NASDAQ:INVA) is the third most undervalued biotech stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Innoviva has a valuation score of 71, which is 56 points higher than the biotech industry average of 15. It passed 5 out of 7 valuation due diligence checks.

Innoviva's stock has gained 15.57% in the past year. It has overperformed other stocks in the biotech industry by 79 percentage points.

64.06% of biotech stocks rated by analysts are a strong buy right now. On average, analysts expect biotech stocks to rise by 81.19% over the next year.

2.01% of biotech stocks have a Zen Rating of A (Strong Buy), 3.8% of biotech stocks are rated B (Buy), 44.97% are rated C (Hold), 37.36% are rated D (Sell), and 11.86% are rated F (Strong Sell).